论文部分内容阅读
目的探讨金水宝胶囊联合替米沙坦治疗原发性肾病综合征的临床疗效。方法选取2012年8月至2013年11月收治的88例原发性肾病综合征的患者。将其随机分为两组,对照组患者单纯采用强的松治疗,观察组患者在对照组的基础上加用金水宝胶囊联合替米沙坦。观察两组治疗前后各项化验指标(24 h尿蛋白定量、血肌酐、血浆清蛋白)的变化及长期进行随访明确各组缓解后的复发率。结果观察组与对照组的各项化验指标均比治疗前好转,但观察组改善情况明显好于对照组,观察组的完全缓解率(56.8%)和总有效率(86.3%)明显高于对照组的完全缓解率(29.5%)和总有效率(65.9%),差异均有统计学意义(均P<0.05)。结论原发性肾综合征的患者采用金水宝胶囊联合替米沙坦进行治疗,疗效高,可明显降低复发率,改善预后。
Objective To investigate the clinical efficacy of Jinshuibao capsule combined with telmisartan in the treatment of primary nephrotic syndrome. Methods Eighty-eight patients with primary nephrotic syndrome who were admitted from August 2012 to November 2013 were enrolled. They were randomly divided into two groups. Patients in the control group were treated with prednisone alone. Patients in the observation group were treated with Jinshuibao capsule combined with telmisartan on the basis of the control group. The changes of various laboratory indexes (24 h urinary protein, serum creatinine and plasma albumin) before and after treatment and the long-term follow-up were observed to determine the relapse rate after each treatment. Results The experimental indexes of the observation group and the control group were better than those before treatment, but the improvement in the observation group was better than that in the control group. The complete remission rate (56.8%) and total effective rate (86.3%) in the observation group were significantly higher than those in the control group The complete response rate (29.5%) and total effective rate (65.9%) were significantly different between the two groups (all P <0.05). Conclusion The patients with primary renal syndrome treated with Jinshuibao capsule combined with telmisartan have high curative effect, which can significantly reduce the recurrence rate and improve the prognosis.